Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P488: Does Statin use reduce the risk of J-pouch related complications in patients with inflammatory bowel disease?ECCO '17 Barcelona
Year: 2017
Authors:

Kaimakliotis P., Lazarev M., Bayless T., Parian A., Brant S., Melia J., Truta B.

Johns Hopkins, Gastroenterology/Medicine, Baltimore, United States

P489: Double-dose infliximab therapy in Crohn's disease: appropriate time to evaluate the efficacy, long-term efficacy and safetyECCO '17 Barcelona
Year: 2017
Authors:

Kunisaki R., Nishio M., Ogashiwa T., Otake H., Inoue E., Kimura H.

Yokohama City University Medical Centre, Inflammatory Bowel Disease Centre, Yokohama, Japan

P490: A pilot study of the electronic patient portal “Patient Knows Best” for monitoring biologic therapy in inflammatory bowel diseaseECCO '17 Barcelona
Year: 2017
Authors:

Kamperidis N., O'Connor M., Crook K., Arebi N.

St Mark's Hospital, London, United Kingdom

P491: Comparison of the durability of response to subcutaneous anti-TNF therapy between ulcerative colitis and Crohn's diseaseECCO '17 Barcelona
Year: 2017
Authors:

Mellotte G.*1,2, McShane C.1,2, O'Connell J.1,2, Mc Kiernan S.1,2, Mac Carthy F.1,2, Kevans D.1,2

1St James's Hospital, Dublin, Ireland 2Trinity College, School of Medicine, Dublin, Ireland

P492: Cumulative safety signal review confirmed the established safety profile of Asacol™† (mesalazine)ECCO '17 Barcelona
Year: 2017
Authors:

Timeus S.*1, Marchi P.2

1Tillotts Pharma, Pharmacovigilance, Rheinfelden, Switzerland 2Tillotts Pharma, Medical Affairs, Rheinfelden, Switzerland

P493: Efficacy of anti-TNF for internal fistula in Crohn's disease – results from a retrospective multicenter cohort studyECCO '17 Barcelona
Year: 2017
Authors:

Kobayashi T.*1, Hishida A.2, Tanaka H.3, Bamba S.4, Yamada A.5, Toshimitsu F.6, Shinichiro S.7, Kamata N.8, Yoshino T.9, Hibi T.1 AIM Jr. Internal Fistula Study Group

1Kitasato University Kitasato Institute Hospital, Center for Advanced IBD Research and Treatment, Tokyo, Japan 2Nagoya University Graduate School of Medicine, Department of Preventive Medicine, Nagoya, Japan 3Sapporo Kosei General Hospital, IBD Center, Sapporo, Japan 4Shiga University of Medical Science, Division of Gastroenterology, Shiga, Japan 5Toho University Sakura Medical Center, Department of Internal Medicine, Chiba, Japan 6Tokyo Medical and Dental University, Department of Gastroenterology and Hepatology, Tokyo, Japan 7Osaka University Graduate School of Medicine, Department of Gastroenterology and Hepatology, Osaka, Japan 8Osaka City University Graduate School of Medicine, Department of Gastroenterology, Osaka, Japan 9Tazuke Kofukai Medical Research Institute Kitano Hospital, IBD Center, Osaka, Japan

P494: Multicentre cohort study to evaluate the need for re-intervention following multimodal treatment in Crohn's disease with perianal fistulaECCO '17 Barcelona
Year: 2017
Authors:

Sebastian S.*1,2, Black C.2, Pugliese D.3, Armuzzi A.3, Sahnan K.4, Elkady S.M.4, Katsanos K.H.5, Christodoulou D.K.5, Selinger C.6, Maconi G.7, Fiorino G.8, Kopylov U.9, Davidov Y.9, Bosca-Watts M.M.10, Ellul P.11, Muscat M.11, Karmiris K.12, Fearnhead N.S.13, Allgar V.14, Hart A.L.4, Ben-Horin S.9, Danese S.8

1Hull & East Yorkshire NHS Trust, Hull, United Kingdom 2Hull & East Yorkshire NHS Trust, IBD Unit, Hull, United Kingdom 3Gemelli Hospital Catholic University, Rome, Italy 4St Marks Hospital, London, United Kingdom 5University of Ioannina, Ioannina, Greece 6Leeds Teaching hospitals NHS Trust, Leeds, United Kingdom 7Louigi Sacco University Hospital, Milan, Italy 8Humanitas Research Hospital, Milan, Italy 9Sheba Medical Center, Tel-Aviv, Israel 10University Clinic Hospital, Valencia, Spain 11Mater Dei Hospital, Msida, Malta 12Venizeleio General Hospital, Crete, Greece 13Addenbrooks University Hospitals, Cambridge, United Kingdom 14University of York, York, United Kingdom

P495: Intensified infliximab rescue therapy for acute severe ulcerative colitis does not improve long term colectomy-free survivalECCO '17 Barcelona
Year: 2017
Authors:

Al Khoury A.*1, Chao C.-y.2, Aruljothy A.2, Wyse J.3, Bessissow T.2

1McGill University, Gastroenterology, Montreal, Canada 2McGill University Health Centre, Department of Gastroenterology, Montréal, Canada 3Jewish General Hospital, Department of Gastroentelrology, Montréal, Canada

P496: Successful dose de-escalation to adalimumab 40mg every three weeks in patients with Crohn's diseaseECCO '17 Barcelona
Year: 2017
Authors:

Ferrante M.*1, Van Steenbergen S.1, Bian S.2, Ballet V.1, Vermeire S.1, Van Assche G.1, Gils A.2

1University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium 2KU Leuven, Laboratory for Therapeutic and Diagnostic Antibodies, Leuven, Belgium

P497: Impacts of mucosal healing on clinical outcomes in patients with refractory ulcerative colitis on tacrolimus or biologicsECCO '17 Barcelona
Year: 2017
Authors:

Yamamoto T., Shimoyama T., Umegae S.

Yokkaichi Hazu Medical Centre, Inflammatory Bowel Disease Centre, Yokkaichi, Japan

P498: Emerging role of the IL-33/ST2 axis in predicting mucosal response to anti-TNF therapy in ulcerative colitisECCO '17 Barcelona
Year: 2017
Authors:

Lopetuso L.R.*1,2, Petito V.3, Graziani C.3, Scannone D.4, Scaldaferri F.5, Pizarro T.T.6, Gasbarrini A.3

1Catholic University of the Sacread Hearth, Internal Medicine, Gastroenterology Division, Rome, Italy 2Case Western Reserve University, Pathology, Cleveland, United States 3Catholic University of Sacred Heart, Internal Medicine Department, Gastroenterology Division, Rome, Italy 4Catholic University of Sacred Heart, Pathology, Rome, Italy 5Catholic University of Sacred Heart, Internal Medicine and Gastroenterology, Rome, Italy 6Case Western Reserve University, Pathology, Cleveland, United States

P499: Sexual dysfunction is frequent among inflammatory bowel disease patients: results of a prospective studyECCO '17 Barcelona
Year: 2017
Authors:

Rivière P.*1, Zallot C.2, Desobry P.3, Sabaté J.-M.4, Vergniol J.1, Zerbib F.1, Peyrin-Biroulet L.2, Laharie D.1, Poullenot F.1

1Bordeaux University Hospital, Bordeaux, France 2Nancy University Hospital, Nancy, France 3Enedis GRDF, Lille, France 4Hôpital Louis-Mourier, Colombes, France

P500: Effectiveness and safety in Crohn's disease patients who were treated with CT-P13ECCO '17 Barcelona
Year: 2017
Authors:

Choe Y.H.*1, Lee S.-H.2, Park D.I.3, Lee J.H.4, Kim H.J.5, Kim Y.-H.6, Choi C.H.7, Eun C.S.8, Lee S.J.9, Lee S.9

1Samsung Medical Center, Sungkyunkwan University School of Medicine, Department of Pediatrics, Seoul, South Korea 2Esoo Hospital, Digestive Endoscopic Center, Cheonan-si, South Korea 3Kangbuk Samsung Hospital, Department of Internal Medicine, Seoul, South Korea 4Seoul Song Do Colorectal Hospital, Department of Internal Medicine, Seoul, South Korea 5Kyung Hee University College of Medicine, Department of Internal Medicine, Seoul, South Korea 6Samsung Medical Center, Sungkyunkwan University School of Medicine, Department of Internal Medicine, Seoul, South Korea 7Chung-Ang University College of Medicine, Department of Internal Medicine, Seoul, South Korea 8Hanyang University Guri Hospital, Hanyang University College of Medicine, Department of Internal Medicine, Guri, South Korea 9CELLTRION, Inc., Incheon, South Korea

P501: Baseline characteristics of Crohn's disease patients in the vedolizumab PASS study: a cohort study assessing the safety and effectiveness of vedolizumab compared to other biologic agents (02)ECCO '17 Barcelona
Year: 2017
Authors:

Siegel C.A.*1, Lichtenstein G.2, Siegmund B.3, Lewis J.D.2, Wolf D.4, Louis E.5, Sebastian S.6, Hebuterne X.7, Bell A.8, Söderman C.9, Schubert S.10, Atreya R.11, Polyak S.12, Hoque S.13, Krummenerl A.14, Bokemeyer B.15, Krummenerl T.16, Shulmann S.17, Karlén P.18, Moum B.19, Dolin P.20

1Dartmouth-Hitchcock Medical Center, Departmnet of Gastroenterology, Lebanon, United States 2University of Pennsylvania Perelman School of Medicine, Division of Gastroenterology, Philadelphia, United States 3Charité - University Hospital Berlin, Campus Benjamin Franklin, Department of Gastroenterology, Berlin, Germany 4Atlanta Gastroenterology Associates, Atlanta, United States 5CHU Liège, Liège, Belgium 6Hull Royal Infirmary, Hull & East Yorkshire Hospitals NHS Trust, Department of Gastroenterology and Hepatology, Hull, United Kingdom 7CHU Archet 2, Department of Gastroenterology, Nice, France 8Weston General Hospital, Weston Area Health Trust - Department of Gastroenterology, Weston Super Mare, United Kingdom 9Capio St Görans Hospital, Stockholm, Sweden 10Praxis für Gastroenterologie, Berlin, Germany 11University Hospital Erlangen, Department of Gastroenterology, Erlangen, Germany 12University of Iowa Health Care, Inflammatory Bowel Diseases & Celiac Disease Center, Iowa City, United States 13Barts Heath NHS Trust, Gastroenterology, London, United Kingdom 14Hospital Martha Maria Doelau, Halle, Germany 15Gastroenterologische Gemeinschaftspraxis Minden, Department of Gastroenterology, Minden, Germany 16Gastroenterologische Praxis am Germania-Campus, Münster, Germany 17Scott Shulman Medical, North Bay, Ontanio, Canada 18Danderyds Hospital, Department of Gastroenterology, Stockholm, Sweden 19Oslo University, Department of Gastroenterology, Oslo, Norway 20Takeda Development Centre Europe, Pharmacoepidemiology, London, United Kingdom

P502: Ulcerative colitis patients on vedolizumab lacking response at induction phase continue to improve over the first 6 months of treatmentECCO '17 Barcelona
Year: 2017
Authors:

Zezos P.*1, Kabakchiev B.2, Weizman A.V.1, Nguyen G.C.1, Narula N.1, Croitoru K.1, Steinhart A.H.1, Silverberg M.S.1

1Mount Sinai Hospital, University of Toronto, Division of Gastroenterology, Toronto, Canada 2Mount Sinai Hospital, Samuel Lunenfeld Research Institute, Toronto, Canada

P503: Rapid point-of-care monitoring of anti-infliximab antibodies in patients with inflammatory bowel disease treated with the reference infliximab or CT-P13 in routine clinical practiceECCO '17 Barcelona
Year: 2017
Authors:

Ametzazurra A.1, Rivera N.2, Hernández A.M.1, Arreba M.P.3, Ruiz E.4, Ortíz J.3, Muñoz M.d.C.3, Torres N.1, Pascual J.1, Martínez A.1, Allande M.J.2, Nagore D.*1

1Progenika Biopharma SA, R&D Department, Derio, Spain 2Hospital de Basurto, Rheumatology, Research Unit, Bilbao, Spain 3Hospital de Basurto, Department of Gastroenterology, Bilbao, Spain 4Hospital de Basurto, Rheumatology, Bilbao, Spain

P504: Differences between paediatric and adult inflammatory bowel disease presentation – analysis based on the data from multicenter, prospective cohort observational study assessing safety of anti-TNF therapy – Satimos studyECCO '17 Barcelona
Year: 2017
Authors:

Sieczkowska-Golub J.*1, Jarzebicka D.1, Borys-Iwanicka A.2, Korlatowicz-Bilar A.3, Szaflarska-Popławska A.4, Grzybowska-Chlebowczyk U.5, Łazowska-Przeorek I.6, Daniluk U.7, Korczowski B.8, Sordyl B.9, Szczepanik M.10, Landowski P.11, Plocek A.12, Bąk-Drabik K.13, Zagorowicz E.14, Kierkus J.1

1The Children's Memorial Health Institute, Department of Gastroenterology, Hepatology, Feeding Disorders and Pediatrics, Warsaw, Poland 2Independent Clinical Public Hospital No. 1, Department of Pediatrics, Gastroenterology and Nutrition, Wroclaw, Poland 3Specialist Independent Public Health Care Centre for Children and Youth, Department of Pediatrics, Gastroenterology and Rheumatology, Szczecin, Poland 4University Hospital in Bydgoszcz, Department of Pediatrics, Allergology and Gastroenterology, Bydgoszcz, Poland 5The Independent Public Clinical Hospital no. 6 of the Medical University of Silesia in Katowice John Paul II Upper Silesian Child Health Centre, Department of Gastroenterology, Katowice, Poland 6Independent Public Children's Hospital in Warsaw, Department of Gastroenterology and Nutrition, Children, Warsaw, Poland 7University Hospital in Białystok, Department of Pediatrics, Gastroenterology and Allergology, Bialystok, Poland 8Regional Clinical Hospital No. 2, Department of Pediatric Gastroenterology, Rzeszow, Poland 9Polish Mother's Memorial Hospital Research Institute, Department of Gastroenterology, Allergy and Pediatrics, Lodz, Poland 10Clinical Hospital of Medical University in Poznan, Department of Gastroenterology and Metabolic Diseases, Poznan, Poland 11University Clinical Center - University Hospital, Department of Gastroenterology, Gdansk, Poland 12Central Hospital of Medical University in Lodz, Department of Allergology, Gastroenterology and Nutrition, Children, Lodz, Poland 13Independent Public Clinical Hospital No. 1 of Silesian Medical University in Katowice, Department of Pediatrics, Katowice, Poland 14Oncology Centre - Institute for them. Maria Sklodowska – Curie in Warsaw, Department of Gastroenterology Oncology, Warsaw, Poland

P505: Efficacy of MMX-mesalamine monotherapy for maintenance of remission in ulcerative colitis patients after mucosal healingECCO '17 Barcelona
Year: 2017
Authors:

Lopez-Diaz J., Ferreiro R., De la Iglesia D., Lorenzo A., Dominguez-Munoz J.E., Barreiro-de Acosta M.

University Hospital Santiago de Compostela, Gastroenterology, Santiago, Spain

P506: Psychological factors and quality of life in inflammatory bowel diseases patients: the Psycho studyECCO '17 Barcelona
Year: 2017
Authors:

Vegni E.1, Gilardi D.2, Corrò B.E.3, Menichetti J.4, Leone D.1, Allocca M.2, Bonovas S.5, Furfaro F.2, Danese S.2,6, Fiorino G.*7

1University of Milan, Department of Health Sciences, Milan, Italy 2Humanitas Research Hospital, IBD Center, Gastroenterology, Rozzano, Milan, Italy 3University of Milan, Milan, Italy 4Catholic University, Department of Psychology, Milan, Italy 5Humanitas Research Hospital, Department of Gastroenterology, IBD Center, Rozzano, Italy 6Humanitas University, Biomedical Sciences, Rozzano, Milan, Italy 7Humanitas Clinical and Research Center, IBD Center, Department of Gastroenterology, Rozzano, Italy

P507: Nutrition status in pre-surgical Crohn's disease, active Crohn's disease, Crohn's disease in remission and ulcerative colitis in remission: a cross-sectional studyECCO '17 Barcelona
Year: 2017
Authors:

Sandall A.M.*1, Patel K.V.2, O'Hanlon D.V.3, Smith S.J.1, Darakhshan A.A.4, Sanderson J.D.2, Lomer M.C.1,3

1King's College London, Diabetes and Nutritional Sciences Division, London, United Kingdom 2Guy's and St Thomas' NHS Foundation Trust, Gastroenterology, London, United Kingdom 3Guy's and St Thomas' NHS Foundation Trust, Nutrition & Dietetics, London, United Kingdom 4Guy's and St Thomas' NHS Foundation Trust, Colorectal Surgery, London, United Kingdom